COGT news

Latest 2 stories · newest Nov 5, 2026

COGT

Cogent Biosciences Reports Q3 2026 Results and Approaches Key FDA Approvals

Cogent Biosciences reported $791.1 million in cash to fund operations and is preparing for the anticipated launch of bezuclastinib, with key regulatory decisions expected in late 2026 and throughout 2027.

Guidance Nov 5, 2026 sentiment +0.50 SEC filing ↗

COGT

Cogent Biosciences highlights business milestones and Q2 2026 financial results.

The company reported strong Q2 2026 cash position, completed onboarding a new customer team, and submitted applications for bezuclastinib. The financial news is relevant as the company is advancing commercialization of a key oncology drug.

Earnings Aug 10, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same COGT feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/COGT/newsSTART FREE